Oberg K
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Curr Opin Oncol. 1994 Jul;6(4):441-51.
Neuroendocrine tumors constitute only 2% of all malignant gastrointestinal tumors but have attracted a lot of scientific interest during the past decade. These tumors are excellent models for studies of new diagnostic and therapeutic tools. During the past year, major breakthroughs have been made in the areas of both diagnosis and therapy, but in particular, the development of somatostatin receptor scintigraphy and positron emission tomography have been major contributions to the diagnosis, localization, and tumor biology. The introduction of somatostatin analogues and interferons alone, or in combinations, have further improved the quality-of-life for patients with these tumors and probably has also prolonged the overall survival. Recent data on the expression of various growth factors, receptors, oncogenes, and tumor-suppressor genes have increased our understanding about the tumor biology. However, we are just at the beginning and to further improve the clinical management of these patients we have to put more effort into areas of molecular genetics and growth regulation of these tumors. This review discusses the recent developments in biology, diagnosis, and treatment of gut neuroendocrine tumors.
神经内分泌肿瘤仅占所有胃肠道恶性肿瘤的2%，但在过去十年中引起了众多科学关注。这些肿瘤是研究新型诊断和治疗工具的理想模型。在过去一年里，诊断和治疗领域均取得了重大突破，尤其是生长抑素受体闪烁扫描术和正电子发射断层扫描的发展，为肿瘤的诊断、定位及肿瘤生物学研究做出了重要贡献。生长抑素类似物和干扰素单独或联合使用，进一步改善了这些肿瘤患者的生活质量，可能还延长了总体生存期。关于各种生长因子、受体、癌基因和肿瘤抑制基因表达的最新数据，加深了我们对肿瘤生物学的理解。然而，我们才刚刚起步，为了进一步改善这些患者的临床管理，我们必须在这些肿瘤的分子遗传学和生长调节领域投入更多精力。本文综述了肠道神经内分泌肿瘤在生物学、诊断和治疗方面的最新进展。
